May 8th 2024
Phase 2 data also highlight an improvement in disease control rate with setanaxib/pembrolizumab in squamous cell carcinoma of the head and neck.
Cetuximab Plus RT Linked With High Toxicity in Head and Neck Cancer
December 10th 2015The combination of radiation therapy plus cetuximab had higher rates of acute toxicity among patients with locally advanced squamous cell carcinoma of the head and neck compared with radiation therapy plus cisplatin.
Increased Risk of Second Malignancies With Radioactive Iodine Therapy for Thyroid Cancer
April 27th 2015A new population-based study has found that patients with thyroid cancer who are treated with radioactive iodine therapy are at increased risk for developing salivary cancer as a second malignancy.
Serum Biomarkers Could Aid in Early Diagnosis of HNSCC
November 23rd 2013A small retrospective study has identified several biomarkers that were significantly altered in patients with head and neck squamous cell carcinoma. If further validated, these serum biomarkers could facilitate early diagnosis.